CYP2C19

From SNPedia
Jump to: navigation, search

is agene
is mentioned by
Full namecytochrome P450, family 2, subfamily C, polypeptide 19
EntrezGene1557
PheGenI1557
VariationViewer1557
ClinVarCYP2C19
dbSNP1557
SADR1557
HugeNav1557
CYPANCcyp2c19
wikipediaCYP2C19
googleCYP2C19
gopubmedCYP2C19
EVSCYP2C19
HEFalMpCYP2C19
23andMeCYP2C19
UniProtP33261
EnsemblENSG00000165841
OMIM124020
EVSCYP2C19
# SNPs25
  Max Magnitude Chromosome position Summary
Rs12248560 2 96,521,657 Clopidogrel (Plavix®)
Rs12767583 96,547,463
Rs17878459 0 94,775,165
Rs17879685 0 96,609,752
Rs17882687 0 96,522,517
Rs17884712 0 96,535,246
Rs28399504 2.5 94,762,706 Clopidogrel (Plavix®)
Rs3758581 0 96,602,623
Rs3814637 96,521,045
Rs41291556 3 96,535,173 Clopidogrel (Plavix®)
Rs4244285 4 94,781,859 Clopidogrel (Plavix®)
Rs4917623 96,609,568
Rs4986893 2.1 94,780,653 Clopidogrel (Plavix®)
Rs55640102 0 96,612,671
Rs55752064 0 96,522,512
Rs56337013 3 94,852,738 Clopidogrel (Plavix®)
Rs57081121 0 94,780,653
Rs5787121 0 96,612,514
Rs58973490 0 96,535,264
Rs6413438 3 96,541,615
Rs6583954 96,534,263
Rs72552267 0 96,535,210
Rs72558184 0 96,535,210 Clopidogrel (Plavix®)
Rs72558185 0 96,541,656
Rs72558186 0 96,541,756 Clopidogrel (Plavix®)
CYP2C19 is a member of the IIC subfamily of the cytochrome p450 genes, responsible for metabolizing or activating some hormones (such as estrogens) and several commonly prescribed drugs, including anti-epileptics (such as diazepam, phenytoin, and phenobarbitone), anti-depressants (such as amitriptyline and clomipramine), the anti-platelet drug clopidogrel (Plavix), the anti-ulcer proton pump inhibitors like omeprazole (trade names Losec and Prilosec), esomeprazole (trade name Nexium), and lansoprazole (Prevacid), and even some hormones (like progesterone).

Asians and Pacific Islanders have a higher incidence of nonfunctional CYP2C19 variants, which may affect treatment for malaria. The antimalarial drug proguanil is metabolized by both CYP2C19 and CYP2D6. [[1]] [[2]]

Generally, with respect to CYP2C19, individuals are classified as rapid metabolizers if they are homozygous for the CYP2C19*1 allele (ie they are CYP2C19*1/CYP2C19*1), intermediate metabolizers if they have one CYP2C19*1 allele plus one variant allele (such as CYP2C19*2 or CYP2C19*3), and poor metabolizers if they carry two copies of a variant. Effective doses are higher for individuals who are poor metabolizers and thus treatment success is higher as well. [PMID 15952098]

SNPs in CYP2C19 include:

Allele Name Rs# Comments Platforms
CYP2C19*1 n/a Wild-type/normal, hence no rs#; genoset gs150
CYP2C19*2 rs4244285 nonfunctional 23andMe v2, 23andMe v3, FTDNA2, HumanOmni1Quad, 23andMe v4
CYP2C19*2B rs17878459 nonfunctional 23andMe v1, 23andMe v2, 23andMe v3, HumanOmni1Quad, 23andMe v4
CYP2C19*3 rs4986893 or rs57081121 poor metabolism of compounds like proguanil and therefore with implications for malaria prophylaxis 23andMe v1, 23andMe v2, 23andMe v3, FTDNA2, FamilyTreeDNA, HumanOmni1Quad, 23andMe v4 and
CYP2C19*4 rs28399504 nonfunctional 23andMe v1, 23andMe v2, 23andMe v3, FTDNA2, FamilyTreeDNA, HumanOmni1Quad, Illumina Human 1M, 23andMe v4
CYP2C19*5 rs56337013 poor metabolizer
CYP2C19*6 rs72552267 nonfunctional 23andMe v3, 23andMe v4
CYP2C19*7 rs72558186 nonfunctional 23andMe v3, 23andMe v4
CYP2C19*8 rs41291556 nonfunctional 23andMe v2, 23andMe v3, FTDNA2, FamilyTreeDNA, 23andMe v4
CYP2C19*9 rs17884712 23andMe v1, 23andMe v2, 23andMe v3, 23andMe v4
CYP2C19*10 rs6413438 23andMe v1, 23andMe v2, 23andMe v3, FTDNA2, HumanOmni1Quad, Illumina Human 1M, 23andMe v4
CYP2C19*11 rs58973490 23andMe v3
CYP2C19*12 rs55640102 23andMe v3, 23andMe v4
CYP2C19*13 rs17879685 23andMe v1, 23andMe v2, 23andMe v3, FTDNA2, HumanOmni1Quad, Illumina Human 1M, 23andMe v4
CYP2C19*14 rs55752064 23andMe v3, 23andMe v4
CYP2C19*15 rs17882687 23andMe v3, 23andMe v4
CYP2C19*17 rs12248560 ultra-rapid metabolizer 23andMe v2, 23andMe v3, 23andMe v4
CYP2C19_80161G>A(V331I) rs3758581 23andMe v2, 23andMe v3, 23andMe v4
CYP2C19_90052delG(G439-) rs5787121 23andMe v1, 23andMe v2, 23andMe v3, 23andMe v4
hCV34328665 rs72558185 23andMe v3, 23andMe v4

CYP2C19 allele nomenclature http://www.cypalleles.ki.se/cyp2c19.htm


Promethease checks this via genosets:

  • gs150 CYP2C19 normal/rapid metabolizer (most likely)
  • gs151 CYP2C19 Intermediate Metabolizer
  • gs152 CYP2C19 Poor Metabolizer
  • gs153 CYP2C19 Extensive or Ultra-Fast Metabolizer


As of May 2011, the CPMC is revealing to it's participants their CYP2C19 status, primarily in order to determine the suitability of taking clopidogrel. Coriell states that they determine CYP2C19 status based on the following SNPs: